Sawai Chalks Up More Than A Dozen Launches

Follows Approvals From Japan's MHLW Earlier This Year

Sawai has followed-up on a raft of approvals announced earlier this year with launch plans, including for the first generics of Daiichi Sankyo’s Memary (memantine hydrochloride) Alzheimer’s disease treatment in three presentations.

Doctor_Clipboard
Sawai sees its expanded Japanese portfolio boosting sales this year • Source: Shutterstock

More from Products

More from Generics Bulletin